Standard BioTools files registration statement for all-stock merger with Treeline Biosciences

Corporate Action
โดย GlobeNewswire·Read original
Summary · why it matters

Standard BioTools has filed a registration statement with the SEC for its all-stock merger with Treeline Biosciences, a clinical-stage biopharma company. The combined company is expected to have over $900 million in pro-forma cash at closing, which is anticipated in the second half of 2026, and will operate as Treeline Biosciences Holdings under the ticker TRLN. The filing highlights Treeline's pipeline, including headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas showing an 84% overall response rate and a 32% complete response rate with no dose-limiting toxicities. Interim data readouts for TLN-121 and TLN-372 are planned for 2027. Treeline also announced that Sue Desmond-Hellmann, former CEO of the Bill & Melinda Gates Foundation, has joined its Board of Directors.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Standard Biotools Inc
LAB
▲ PositiveCapitalrelevance

Standard BioTools is merging with Treeline Biosciences, creating a combined entity with over $900M cash and a promising pipeline, which is positive for Standard BioTools shareholders.

Off-coverage companies 1

Treeline BiosciencesPrivate▲ Positive
Capitalrelevance

Treeline Biosciences is the acquirer in an all-stock merger, gaining public listing and access to capital markets, with strong Phase 1 data for TLN-121.

© 2026 MarketDXNews